Phase 2
N=7
Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations
Frontotemporal Lobar Degeneration (FTLD) · Frontotemporal Dementia (FTD) · Tauopathies
Bottom Line
View on ClinicalTrials.gov: NCT02676843 ↗Enrolled (actual)
7
Serious AEs
0.0%
Results posted
Dec 2019
Primary outcome: Primary: SUVR of 18F-AV-1451 — 1.07; 1.26; 1.03; 1.34 standardized uptake value ratio (SUVR)
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- 18F-AV-1451 (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Columbia University
- Primary completion
- Nov 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY SUVR of 18F-AV-1451 |
1.07; 1.26; 1.03; 1.34 | — |
Summary
The study will investigate the ability of a new PET tracer, 18F-AV-1451, to detect depositions of a protein, called tau, in the brains of people with a mutation in the tau gene that causes deposition of the protein, and in people without the mutation. Up to three 18F-AV-1451 scans will be performed (one per year) on control subjects without MAPT mutations, presymptomatic mutation carriers, and symptomatic mutation carriers.
Eligibility Criteria
Inclusion Criteria
- Members of families with established MAPT mutations, who either have the capacity to consent to participate in the protocol, or else have designated a surrogate/proxy to consent to participate in this study
Exclusion Criteria
- Unwillingness to participate
- Usage of medication which significantly prolongs QT interval
- Pregnancy or plans for pregnancy within 90 days after participating in study
Data sourced from ClinicalTrials.gov (NCT02676843). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.